Related Experiment Video

Updated: May 28, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Community-acquired pneumonia due to Panton-Valentine leukocidin-producing Staphylococcus aureus in an HIV-2-infected

C Daneshvar1, N C Smith, D J Waghorn

  • 1Department of Thoracic Medicine,Wycombe Hospital, High Wycombe, UK. cyrus_daneshvar@hotmail.com

International Journal of STD & AIDS
|October 15, 2011
PubMed

Insights

Severe pneumonia caused by Panton-Valentine leukocidin-producing Staphylococcus aureus is rare in HIV-2 patients. This case highlights a fatal outcome in an HIV-2 co-infected individual, emphasizing the need for awareness.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Immunology

Background:

  • Panton-Valentine leukocidin (PVL)-producing Staphylococcus aureus is a significant cause of severe community-acquired pneumonia.
  • Co-infection with human immunodeficiency virus (HIV) can alter the course and severity of infectious diseases.
  • Few cases of PVL-producing S. aureus pneumonia have been reported in HIV-1 co-infected patients.

Observation:

  • A fatal case of severe community-acquired pneumonia is presented.
  • The patient was a 45-year-old woman.
  • The causative agent was identified as Panton-Valentine leukocidin-producing Staphylococcus aureus.

Findings:

  • The patient had a co-infection with human immunodeficiency virus type 2 (HIV-2).
  • The pneumonia led to a fatal outcome.
  • This represents a rare instance of severe PVL-S. aureus pneumonia in an HIV-2 positive individual.

Implications:

  • This case underscores the potential severity of PVL-S. aureus infections in immunocompromised individuals, specifically those with HIV-2.
  • It highlights the importance of considering PVL-S. aureus in severe pneumonia, even in patients with HIV co-infection.
  • Further research may be warranted to understand the interaction between HIV-2 and PVL-S. aureus pathogenicity.

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: